Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

PMs-Ti4+-based plasma extracellular vesicles glycoproteomics and its application in lung cancer

ABSTRACT: PMs-Ti⁴⁺ enables glycoproteomic analysis that integrates EVs capture and in-situ enzymatic digestion. It can directly identify intact N-glycopeptides in plasma EVs. This study reveals protein expression and glycosylation remodeling in plasma EVs from lung cancer

ORGANISM(S): Homo Sapiens

SUBMITTER: Xiuling Li

PROVIDER: PXD076361 | iProX | Tue Mar 31 00:00:00 BST 2026

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

PMs-Ti<sup>4+</sup>-based plasma extracellular vesicles glycoproteomics and its application in lung cancer.

Zheng Xinxin X Xiong Fangfang F Zhao Yanyan Y Li Xiuling X Liu Zhiyu Z Liang Xinmiao X

Analytica chimica acta 20260401

Extracellular vesicles (EVs) are densely decorated with glycoproteins and serve as pivotal molecular reservoirs in liquid biopsies. However, existing EV glycoproteomic analyses typically involve complex procedures such as EV enrichment, in-solution enzymatic digestion, glycopeptide enrichment, and N-glycosylation removal, making it difficult to obtain intact N-glycopeptide information. This study developed an analytical method based on Ti<sup>4+</sup>-functionalized porous microparticles (PMs-Ti ...[more]

PMID: 42009414

Similar Datasets

Glycoproteomics of human THP-1-derived M0, M1 and M2 macrophages

Project description:In this study, we used human THP-1-derived macrophages as an immune cell model, and systematically performed glycoproteomics of three subtypes of macrophages by StrucGP.To study the N‑Glycoproteomic of them, the intact glycopeptides were first enriched and identified using triplicate mass spectrometry (MS)-based glycoproteomic approaches, then StrucGP was used for subsequent analysis. In total three subtypes of macrophages, these intact glycopeptides consist of 253 N-linked glycan structures at 652 unique glycosites from 372 N-glycoproteins, along with their PSM information. A total of 135, 163, and 201 N-glycan structures were identified from M0, M1, and M2 macrophages, respectively.

2023-10-19 | PXD030277 | Pride

Glyco-CPLL: an integrated method for in-depth and comprehensive N-glycoproteome profiling of human plasma

Project description:N-glycoproteins are involved in various biological processes. Certain distinctive glycoforms on specific glycoproteins enhance the specificity and/or sensitivity of cancer diagnosis. Therefore, the characterization of plasma N-glycoproteome is essential for new biomarker discovery. Absence of suitable analytical methods for in-depth and large-scale analyses of low-abundance plasma glycoproteins make it challenging to investigate the role of glycosylation. In this study, we developed an integrated method termed Glyco-CPLL, which integrates combinatorial peptide ligand libraries, high-pH reversed-phase pre-fractionation, hydrophilic interaction chromatography, trypsin and PNGase F digestion, shotgun proteomics, and various analysis software (MaxQuant and pGlyco2.0) for the low-abundance plasma glycoproteomic profiling. Then, we utilized the method to perform a comparative study and to explore papillary thyroid carcinoma-related proteins and glycosylations with reference to healthy controls. Finally, a large and comprehensive human plasma N-glycoproteomic database was established, containing 786 proteins, 369 N-glycoproteins, 862 glycosites, 171 glycan compositions, and 1644 unique intact N-glycopeptides. Additionally, several low-abundance plasma glycoproteins were identified, including SVEP1 (~0.54 ng/mL), F8 (~0.83 ng/mL), ADAMTS13 (~1.2 ng/mL). These results suggest that this method will be useful for analyzing plasma intact glycopeptides in future studies. Besides, the Glyco-CPLL method has a great potential to be translated to clinical applications.

2020-01-09 | PXD016428 | Pride

Improving quantitative glycoproteomics by systematic evaluation of different glycopeptide enrichment, quantification, and mass spectrometry strategies

Project description:In this study, we conducted a systematic investigation into a glycoproteomic workflow. Firstly, Label-free and TMT labeling strategies were utilized for intact N-glycopeptide quantification. A total of 2,924 unique intact N-glycopeptides can be quantified after being labeled using TMT approach. Compared to label-free method, TMT labeling for its high precision with the CV averaging 8% and multiplex analysis capabilities. Subsequently, we compared the capacity of ZIC-HILIC and MAX enrichment methods, revealing that the ZIC- HILIC method demonstrated superior performance in enriching intact N-glycopeptides, which can identify 3,004 GPSMs from a single injection of patient-derived xenograft (PDX) sample. Furthermore, we systematically evaluated different higher-energy collisional dissociation (HCD) collision energies, determining that the stepped collision energy HCD (sceHCD) settings of 25, 35, and 45 was the optimal for both the identification and quantification of intact N-glycopeptides.

2025-05-07 | PXD054874 | Pride

Sequential phosphoproteomics and N-glycoproteomics of plasma-derived extracellular vesicles

Project description:Extracellular vesicles (EVs) are increasingly recognized as important cargos for intercellular communication and promising sources for less invasive biomarker discovery. As the state of protein post-translational modifications (PTMs) such as phosphorylation and glycosylation can be a key determinant of cellular physiology such as early stage cancer, comprehensive characterization of protein PTMs in EVs are highly valuable, but significant challenges remain. Recently we demonstrated the feasibility to isolate and identify phosphoproteins and glycoproteins in EVs from human plasma as potential markers to differentiate disease from healthy states. We identified close to 10,000 unique phosphopeptides and 1,500 unique glycopeptides in EVs isolated from small volumes of plasma samples. Using label-free quantitative phospho- and glyco-proteomics, we identified a number of phosphoproteins and glycoproteins in plasma EVs that are significantly higher in patients diagnosed with breast cancer. Here we present an updated workflow to sequentially isolate phosphopeptides and N-glycopeptides, enabling multiple PTM analyses with the same clinical samples and presenting intriguing functional molecules for further validation.

2019-09-25 | PXD013893 | Pride

Characterization of sialylated N- and O-glycopeptides from complex proteomes on an Orbitrap Fusion Tribrid mass spectrometer by Isotope Targeted Glycoproteomics (IsoTaG). Application to azido and alkynyl sugars

Project description:Protein glycosylation is a post-translational modification (PTM) responsible for many aspects of proteomic diversity and biological regulation. Correlation of the intact glycoform to the protein attachment site is a critical step to assign functional roles to specific glycoproteins. Isotope targeted glycoproteomics (IsoTaG) is a mass-independent mass spectrometry method to characterize intact, metabolically labeled glycopeptides from complex proteomes. IsoTaG was applied to conditioned media from PC-3 cells labeled with alkynyl or azido sugars to reveal the sialylated glycoproteome. Analysis on an Orbitrap Fusion Tribrid mass spectrometer resulted in characterization of 699 intact glycopeptides from 192 glycoproteins. These intact glycopeptides represent a total of eight sialylated glycoforms across 126 Nand 576 O-glycopeptides. IsoTaG is an effective platform for identification of intact glycopeptides labeled by alkynyl or azido-glycans and will facilitate further studies on the role of the glycoproteome in biology.

2017-02-22 | PXD004302 | Pride

Glycoproteomics with AI-ETD - Capturing site-specific heterogeneity with large-scale N-glycoproteome analysis

Project description:Protein glycosylation is a highly important, yet a poorly understood protein post-translational modification. Thousands of possible glycan structures and compositions create potential for tremendous site heterogeneity and analytical challenge. A lack of suitable analytical methods for large-scale analyses of intact glycopeptides has ultimately limited our abilities to both address the degree of heterogeneity across the glycoproteome and to understand how it contributes biologically to complex systems. Here we show that N-glycoproteome site-specific microheterogeneity can be captured at a global level via glycopeptide profiling with activated ion electron transfer dissociation (AI-ETD), enabling characterization of nearly 2,100 N-glycosites (> 7,500 unique N-glycopeptides) from mouse brain tissue. Moreover, we have used this unprecedented scale of glycoproteomic data to develop several new visualizations that will prove useful for analyzing intact glycopeptides in future studies. Our data reveal that N-glycosylation profiles can differ between subcellular regions and structural domains and that N-glycosite heterogeneity manifests in several different forms, including dramatic differences in glycosites on the same protein.

2019-04-02 | PXD011533 | Pride

pGlycoQuant with a deep residual network for quantitative glycoproteomics at intact glycopeptide level enabling the functional exploration of site-specific glycosylation

Project description:Interpreting large-scale glycoproteomic data for intact glycopeptide identification has been tremendously advanced by software tools. However, software tools for quantitative analysis of intact glycopeptides remain lagging behind, which greatly hinders exploring the differential expression and functions of site-specific glycosylation in organisms. Here, we report pGlycoQuant, a generic software tool for quantitative intact glycopeptide analysis, supporting both primary and tandem mass spectrometry quantitation for multiple quantitative strategies. pGlycoQuant advances in glycopeptide evidence matching through applying a deep learning model that reduces missing values for glycopeptide quantification by over 60% compared with Byologic, MSFragger-Glyco and Skyline, as well as an optional function of Match-In-Run (MIR) algorithm for more quantitative coverage of glycopeptides, thus greatly expanding the quantitative function of several powerful search engines, currently including pGlyco 2.0, pGlyco3, Byonic and MSFragger-Glyco. The pGlycoQuant-based site-specific N-glycoproteomic study conducted here quantifies 6435 intact N-glycopeptides in three hepatocellular carcinoma cell lines with different metastatic potentials and, together with in vitro molecular biology experiments, illustrates core fucosylation at site 979 of the L1 cell adhesion molecule (L1CAM) as a potential regulator of HCC metastasis. pGlycoQuant is freely available at https://github.com/Power-Quant/pGlycoQuant/releases. We have demonstrated pGlycoQuant to be a powerful tool for the quantitative analysis of site-specific glycosylation and the exploration of potential glycosylation-related biomarker candidates, and we expect further applications in glycoproteomic studies.

2022-05-16 | MSV000089484 | MassIVE

Autonomous Dissociation-type Selection for Glycoproteomics using a Real-Time Library Search

Project description:Tandem mass spectrometry (MS/MS) is the gold standard for intact glycopeptide identification, enabling peptide sequence elucidation and site-specific localization of glycan compositions. Beam-type collisional activation is generally sufficient for N-glycopeptides, while electron-driven dissociation is crucial for site localization in O-glycopeptides. Modern glycoproteomic methods often employ multiple dissociation techniques within a single LC-MS/MS analysis, but this approach frequently sacrifices sensitivity when analyzing multiple glycopeptide classes simultaneously. Here we explore the utility of intelligent data acquisition for glycoproteomics through real-time library searching (RTLS) to match oxonium ion patterns for on-the-fly selection of the appropriate dissociation method. By matching dissociation method with glycopeptide class, this autonomous dissociation-type selection (ADS) generates equivalent numbers of N-glycopeptide identifications relative to traditional beam-type collisional activation methods while also yielding comparable numbers of site-localized O-glycopeptide identifications relative to conventional electron transfer dissociation-based methods. The ADS approach represents a step forward in glycoproteomics throughput by enabling site-specific characterization of both N-and O-glycopeptides within the same LC-MS/MS acquisition.

2024-11-15 | PXD055054 | Pride

Intact N-glycopeptide signatures of immunoglobulin G molecules in plasma from patients with prostate carcinoma and benign prostatic hyperplasia

Project description:Benign prostatic hyperplasia (BPH) is difficult to discriminate from prostate carcinoma (PCa) preoperatively. The non-invasive biomarkers are necessary to reduce the burden of biopsies and improve survival quality of patients. Previous research suggests that abnormal glycosylation of immunoglobulin gamma molecules (IgGs) may associated with immunological diseases and prostate diseases. Hence, characterizing intact N-glycopeptides of IgGs that correspond to N-glycan structure with specific site information enable better understanding of the molecular pathogenesis and finding out some novel signatures in preoperative discrimination of BPH from PCa. In this study, we profiled intact N-glycopeptides of purified IgGs from 51 PCa patients and 45 BPH patients by our developed N-glycoproteomic method using hydrophilic interaction liquid chromatography enrichment coupled with high resolution LC-MS/MS, and intact N-glycopeptides quantitative analysis was performed using pGlyco 2.0 and MaxQuant softwares. Our data provided plasma IgG subclass-specific and site-specific N-glycosylation quantitative information.

2020-06-29 | PXD016175 | Pride

EThcD-sceHCD-MS/MS-based Clinical N-glycoproteomics

Project description:Site-specific N-glycosylation characterization requires intact N-glycopeptide analysis based on suitable tandem mass spectrometry (MS/MS) method. Electron-transfer/higher-energy collisional dissociation (EThcD), stepped collision energy/higher-energy collisional dissociation (sceHCD), and higher-energy collision dissociation-product-dependent electron-transfer dissociation (HCD-pd-ETD) have emerged as valuable approaches for clinical glycoproteomics. However, each of them incurs some compromise, necessitating the performance comparisons when applied to the analysis of complex clinical samples (e.g., plasma, urine, cells, and tissue). Herein, we developed a hybrid mass spectrometry fragmentation method, EThcD-sceHCD, by combining EThcD and sceHCD. Moreover, we compared the performance of this method with those previous approaches (EThcD, sceHCD, HCD-pd-ETD, and sceHCD-pd-ETD) in the intact N-glycopeptide analysis, and determined its applicability for clinical N-glycoproteomic study.

2022-04-04 | PXD030288 | Pride